First Reported Activity of Sunitinib in the Context of Platinum-Resistant Endometrioid Ovarian Cancer

    loading  Checking for direct PDF access through Ovid


AbstractThe appearance of ovarian cancer is a situation in which conventional chemotherapy provides no adequate solutions. Developing new drugs with new mechanisms of action is clearly required. Sunitinib, because of its action mechanism—inhibiting vascular endothelial growth factor, platelet-derived growth factor, and c-Kit, vital marker paths for survival of ovarian cancer cells as well as its stem cells—can have an important role in the treatment of patients with this disease. We present a clinical case of platinum-resistant ovarian cancer in which sunitinib demonstrates activity in such a difficult clinical context.

    loading  Loading Related Articles